Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
MIDAS Sales by Disease Insights Series #7
Immunology: The state of the market today
Aaron Wright, Analyst, EMEA Thought Leadership
Dec 20, 2021
  • Blogs
  • MIDAS Sales by Disease Insights Series 7

The immunology market is an area of great interest in the pharmaceutical industry. High-value medicines and large potential patient populations make it an attractive therapy area. Indeed, the world’s best-selling drug for the past decade, Humira, is an immunology product. In this first article, we will look at the current state of the immunology market. In subsequent articles we will look towards the future, including what diseases are getting the attention of the pharma industry and potential trends to take note of.

Firstly, we should understand where immunology sits as a market compared to other therapy areas. As shown in figure 1a, whilst oncology remains the largest market by overall value, immunology shows the highest short and long-term growth rates, of 16.5% and 17.1% respectively. In addition, figure 1b highlights how immunology sales comprise a quarter of the overall growth in the market in the past five years.

The US has been the primary driver of this growth, accounting for over three quarters of the immunology sales increase since 2016. It is also, as figure 2b shows, the most valuable region for immunology with over $85bn in sales in the past year at list prices.

However, as figure 2a illustrates this growth has been slowing, having nearly halved from its 2016 growth rate. This is in comparison to the Pharmerging market, where growth has increased dramatically. Whilst its overall market share remains small, the continued rapid growth in China, both in terms of innovation and regulatory strength, means that this may change in the future.

In terms of sales by molecule, Adalimumab retains the largest share with over $30bn sales globally in the past year. Whilst this molecule may make up the bulk of sales currently, US LOE in 2023 will increase biosimilar erosion for the molecule. In general, the bulk of immunology sales is comprised of a handful of molecules; the top five selling molecules in 2021 make up around 60 per cent of the total market, as figure 3 highlights. The multi-indicationality of many immunology products is something we will investigate further in a future article.

Immunology is also a highly specialised field, and this is reflected in the breakdown of molecules we see. Figure 4 shows how the overwhelming majority of immunology sales are classified as specialty medicines. A similar trend is seen between biologics and small molecules, with nearly ninety per cent of sales in the past year coming from biologics. Again, this is perhaps not surprising due to the enormous success of specialty biologics in immunology, such as Adalimumab and Ustekinumab.

The splits in volume, however, are completely different, as shown in figure 5. The share of biologics versus small molecules is opposite as to what we see in the sales value, with ninety per cent of volume sales coming from small molecules. Here we can see the distinction between low volume, high-value specialty molecules, and high volume and low-value traditional molecules such as methotrexate.

In the next article we will take a more granular look at the immunology market and investigate sales for specific indications.

To learn more about IQVIA MIDAS Sales by Disease, Click here.

Contact Us